— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.
— Total revenues increased by 4% to $3.67 billion versus $3.54 billion expected.
— Total product revenues rose by 4% driven by growth in multiple sclerosis drugs, spinal muscular atrophy drug Spinraza, biosimilars Benepali, Imraldi, and Flixabi.
— Research and development expense rose by 13% due to the inclusion of charges related to Samsung Bioepis transaction, related to the option exercise with Ionis Pharmaceuticals, and related to collaboration agreements with CAMP24 Therapeutics and Catalyst Biosciences.
— Looking ahead into the full year 2020, the company expects revenue in the range of $14-14.3 billion and adjusted earnings in the range of $31.50-33.50 per share. Analysts expect EPS of $33.03 on revenue of $14.06 billion.
— The earnings are anticipated to be in the range of $29.50-31.50 per share for the full year.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
